Recursion (RXRX) Insider Report: Gibson Converts and Sells 100k Shares
Rhea-AI Filing Summary
Christopher Gibson, Chief Executive Officer and Director of Recursion Pharmaceuticals (RXRX), reported transactions dated 08/26/2025. The filing shows a conversion/acquisition of 100,000 shares (reported as Class A Common Stock acquired at $0) and a contemporaneous sale of 100,000 Class A shares at $4.84 each, leaving him with 954,229 Class A shares following the sale. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025. The report also lists multiple derivative holdings and stock options with exercise prices and outstanding amounts, including options exercisable for 1,050,567, 666,898, 813,600, 399,002, 5,436, and 282,500 Class A shares at various strike prices. Certain shares are held indirectly through entities and trusts for which Gibson is a manager or trustee.
Positive
- Transaction executed under Rule 10b5-1 plan, indicating pre-arranged trading and procedural compliance
- Detailed disclosure of indirect holdings through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust
- Comprehensive listing of outstanding stock options with exercise prices and vesting notes for investor clarity
Negative
- Insider sale of 100,000 shares at $4.84 each, which represents insider liquidity rather than new insider buying
Insights
TL;DR: Routine insider activity: conversion and a sale executed under a pre-established 10b5-1 plan; overall ownership remains substantial.
The Form 4 discloses that Christopher Gibson executed a conversion/acquisition of 100,000 Class A shares and sold 100,000 Class A shares on 08/26/2025, with the sale priced at $4.84 per share. The filing explicitly notes the trades were pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025, which indicates the sale was prearranged rather than ad hoc. Gibson retains significant equity exposure through direct holdings and substantial outstanding stock options across multiple strike prices. For investors, this is a transparent, preplanned liquidity event rather than an unscheduled insider disposition.
TL;DR: Governance signals are neutral: transactions occurred under an acknowledged 10b5-1 plan and include indirect holdings via affiliated entities.
The filing identifies Gibson as both CEO and a director and discloses indirect ownership through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust, with explicit statements of his roles (member/manager/trustee). The use of a documented 10b5-1 plan and the attorney-in-fact signature provide procedural compliance. The report lists multiple option grants with vesting schedules and varying exercise prices, which are clearly itemized. These disclosures align with standard governance transparency for executive transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 100,000 | $0.00 | -- |
| Conversion | Class A Common Stock | 100,000 | $0.00 | -- |
| Sale | Class A Common Stock | 100,000 | $4.84 | $484K |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
